Vitamin D in the management of Childhood Atopic Dermatitis (eczema)
In children aged 2-16 with moderate to severe atopic dermatitis (eczema), is daily vitamin D3 (1000 IU/day) more effective than placebo in improving the severity of the eczema and quality of life.
Prof Dianne Campbell
150 participants
Mar 11, 2013
Interventional
Conditions
Summary
The project aims to show that oral vitamin D supplementation will improve the severity of childhood atopic dermatitis (eczema). We will compare the severity of disease in children with moderate-severe atopic dermatitis after 3 months of daily Vitamin D therapy or placebo, using randomised double blind placebo controlled methodology. We propose that the severity of moderate and moderate-severe atopic dermatitis will be significantly decreased by oral Vitamin D therapy. We aim to show that in these children, following 3 months of daily vitamin D3 at 1000IU, there will be a significant decrease in their disease severity and decreased use of topical corticosteroids. We aim to demonstrate a significant improvement in the quality of life for these children, as measured by a validated quality of life questionnaire.
Eligibility
Plain Language Summary
Simplified for easier understanding
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Eligible children recruited and enrolled will be randomised to receive either liquid drops of Vitamin D 3 (Cholecalciferol)(1000 IU/day) or placebo for a period of 3 months. All children enrolled will be allowed to continue their normal skin care regime, with use of moisturisers and topical steroids throughout the study period.
Locations(1)
View Full Details on ANZCTR
For the most up-to-date information, visit the official listing.
ACTRN12612000570886